Neoadjuvant and postoperative chemotherapy with paclitaxel p
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Case report
A 31-year-old woman at 19+0 weeks of gestation was referred to our institution for evaluation of cervical mass. A cervical biopsy revealed a moderately differentiated mucinous adenocarcinoma. Magnetic resonance imaging (MRI) confirmed a 2.8-cm-sized cervical mass without vaginal and parametrial involvement. The patient was diagnosed to have FIGO stage IB1 disease. After comprehensive counseling, the written informed consent and institutional review board approval were obtained to start NACT. NACT consisting of paclitaxel 135 mg/m2 plus cisplatin 60 mg/m2 every 3 weeks was given at 22 weeks' gestation. Two additional NACT was administered at 25 and 28 weeks, respectively. However, the patient refused additional NACT and wanted to schedule the delivery of her baby. Fetal well-being was shown by ultrasonographic evaluation before surgery. In addition, fetal pulmonary maturity was confirmed by amniocentesis and the concentration of lecithin is above twice that of spingomyelin. She underwent cesarean section at 33+0 weeks' gestation, and then followed by type III RH with pelvic and para-aortic lymphadenectomy. Final histology revealed a 1.0 cm sized mucinous adenocarcinoma without deep stromal invasion (DSI). Although lymph-vascular space invasion (LVSI) was identified, there was no tumor infiltration to the adjacent vaginal cuff and parametrium and all 26 lymph nodes harvested were tumor negative. Eight years later, the patient did not show any evidence of disease recurrence, and her child is developing normally......